Published in

National Academy of Sciences, Proceedings of the National Academy of Sciences, 19(107), p. 8730-8735, 2010

DOI: 10.1073/pnas.1002769107

Links

Tools

Export citation

Search in Google Scholar

Prolonged antigen survival and cytosolic export in cross-presenting human T cells

Journal article published in 2010 by Simone Meuter, Matthias Eberl ORCID, Bernhard Moser
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Human blood Vgamma9Vdelta2 T cells respond to signals from microbes and tumors and subsequently differentiate into professional antigen-presenting cells (gammadelta T-APCs) for induction of CD4(+) and CD8(+) T cell responses. gammadelta T-APCs readily take up and degrade exogenous soluble protein for peptide loading on MHC I, in a process termed antigen cross-presentation. The mechanisms underlying antigen cross-presentation are ill-defined, most notably in human dendritic cells (DCs), and no study has addressed this process in gammadelta T-APCs. Here we show that intracellular protein degradation and endosomal acidification were significantly delayed in gammadelta T-APCs compared with human monocyte-derived DCs (moDCs). Such conditions are known to favor antigen cross-presentation. In both gammadelta T-APCs and moDCs, internalized antigen was transported across insulin-regulated aminopeptidase (IRAP)-positive early and late endosomes; however, and in contrast to various human DC subsets, gammadelta T-APCs efficiently translocated soluble antigen into the cytosol for processing via the cytosolic proteasome-dependent cross-presentation pathway. Of note, gammadelta T-APCs cross-presented influenza antigen derived from virus-infected cells and from free virus particles. The robust cross-presentation capability appears to be a hallmark of gammadelta T-APCs and underscores their potential application in cellular immunotherapy.